Slingshot members are tracking this event:

AbbVie's HUMIRA (adalimumab) Receives U.S. Food and Drug Administration Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 30, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Humira, Adalimumab, Non-infectious Uveitis, Vision Impairment, Non-corticosteroid Therapy, Tnf-α, Visual-i, Visual-ii